{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T17:10:12Z","timestamp":1790788212278,"version":"4.1.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T00:00:00Z","timestamp":1704758400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.eclinm.2024.102433","type":"journal-article","created":{"date-parts":[[2024,1,25]],"date-time":"2024-01-25T22:34:07Z","timestamp":1706222047000},"page":"102433","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"special_numbering":"C","title":["Rycal S48168 (ARM210) for RYR1-related myopathies: a phase one, open-label, dose-escalation trial"],"prefix":"10.1016","volume":"68","author":[{"given":"Joshua J.","family":"Todd","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tokunbor A.","family":"Lawal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene C.","family":"Chrismer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Kokkinis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Grunseich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minal S.","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa R.","family":"Waite","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Biancavilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shavonne","family":"Pocock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kia","family":"Brooks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"Mendoza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gina","family":"Norato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willa","family":"Riekhof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pooja","family":"Varma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Colina-Prisco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magalie","family":"Emile-Backer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine G.","family":"Meilleur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew R.","family":"Marks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yael","family":"Webb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4206-2168","authenticated-orcid":false,"given":"Eugene E.","family":"Marcantonio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Reghan","family":"Foley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5930-2324","authenticated-orcid":false,"given":"Carsten G.","family":"B\u00f6nnemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5313-9514","authenticated-orcid":false,"given":"Payam","family":"Mohassel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.eclinm.2024.102433_bib1","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s13395-020-00243-4","article-title":"Ryanodine receptor 1-related disorders: an historical perspective and proposal for a unified nomenclature","volume":"10","author":"Lawal","year":"2020","journal-title":"Skeletal Muscle"},{"issue":"4","key":"10.1016\/j.eclinm.2024.102433_bib2","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1002\/ana.22510","article-title":"Prevalence of congenital myopathies in a representative pediatric United States population","volume":"70","author":"Amburgey","year":"2011","journal-title":"Ann Neurol"},{"issue":"23","key":"10.1016\/j.eclinm.2024.102433_bib3","doi-asserted-by":"crossref","first-page":"4087","DOI":"10.1093\/hmg\/ddac145","article-title":"Updated variant curation expert panel criteria and pathogenicity classifications for 251 variants for RYR1-related malignant hyperthermia susceptibility","volume":"31","author":"Johnston","year":"2022","journal-title":"Hum Mol Genet"},{"issue":"1","key":"10.1016\/j.eclinm.2024.102433_bib4","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1097\/ALN.0000000000001878","article-title":"Malignant hyperthermia in the post-genomics era: new perspectives on an old concept","volume":"128","author":"Riazi","year":"2018","journal-title":"Anesthesiology"},{"issue":"6","key":"10.1016\/j.eclinm.2024.102433_bib5","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.nmd.2011.03.006","article-title":"King-Denborough syndrome with and without mutations in the skeletal muscle ryanodine receptor (RYR1) gene","volume":"21","author":"Dowling","year":"2011","journal-title":"Neuromuscul Disord"},{"issue":"6","key":"10.1016\/j.eclinm.2024.102433_bib6","doi-asserted-by":"crossref","DOI":"10.1093\/braincomms\/fcac292","article-title":"Neuromuscular symptoms in patients with RYR1-related malignant hyperthermia and rhabdomyolysis","volume":"4","author":"van den Bersselaar","year":"2022","journal-title":"Brain Commun"},{"issue":"3","key":"10.1016\/j.eclinm.2024.102433_bib7","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.coph.2008.01.005","article-title":"Congenital muscle disorders with cores: the ryanodine receptor calcium channel paradigm","volume":"8","author":"Treves","year":"2008","journal-title":"Curr Opin Pharmacol"},{"issue":"4","key":"10.1016\/j.eclinm.2024.102433_bib8","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1093\/brain\/79.4.610","article-title":"A\u00a0new congenital non-progressive myopathy","volume":"79","author":"Shy","year":"1956","journal-title":"Brain"},{"key":"10.1016\/j.eclinm.2024.102433_bib9","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/1750-1172-8-117","article-title":"Genotype-phenotype correlations in recessive RYR1-related myopathies","volume":"8","author":"Amburgey","year":"2013","journal-title":"Orphanet J Rare Dis"},{"issue":"11","key":"10.1016\/j.eclinm.2024.102433_bib10","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a003996","article-title":"Ryanodine receptors: structure, expression, molecular details, and function in calcium release","volume":"2","author":"Lanner","year":"2010","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"2","key":"10.1016\/j.eclinm.2024.102433_bib11","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.cmet.2011.05.014","article-title":"Ryanodine receptor oxidation causes intracellular calcium leak and muscle weakness in aging","volume":"14","author":"Andersson","year":"2011","journal-title":"Cell Metab"},{"issue":"1","key":"10.1016\/j.eclinm.2024.102433_bib12","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.cell.2008.02.042","article-title":"RyR1 S-nitrosylation underlies environmental heat stroke and sudden death in Y522S RyR1 knockin mice","volume":"133","author":"Durham","year":"2008","journal-title":"Cell"},{"issue":"7","key":"10.1016\/j.eclinm.2024.102433_bib13","doi-asserted-by":"crossref","first-page":"424","DOI":"10.3390\/metabo11070424","article-title":"Altered Ca(2+) handling and oxidative stress underlie mitochondrial damage and skeletal muscle dysfunction in aging and disease","volume":"11","author":"Michelucci","year":"2021","journal-title":"Metabolites"},{"issue":"3","key":"10.1016\/j.eclinm.2024.102433_bib14","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nm.1916","article-title":"Hypernitrosylated ryanodine receptor calcium release channels are leaky in dystrophic muscle","volume":"15","author":"Bellinger","year":"2009","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.eclinm.2024.102433_bib15","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1096\/fj.201700182RRR","article-title":"Ryanodine channel complex stabilizer compound S48168\/ARM210 as a disease modifier in dystrophin-deficient mdx mice: proof-of-concept study and independent validation of efficacy","volume":"32","author":"Capogrosso","year":"2018","journal-title":"FASEB J"},{"issue":"6","key":"10.1016\/j.eclinm.2024.102433_bib16","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1007\/s00401-020-02150-w","article-title":"Intracellular calcium leak as a therapeutic target for RYR1-related myopathies","volume":"139","author":"Kushnir","year":"2020","journal-title":"Acta Neuropathol"},{"issue":"7","key":"10.1016\/j.eclinm.2024.102433_bib17","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/j.str.2022.04.010","article-title":"A\u00a0drug and ATP binding site in type 1 ryanodine receptor","volume":"30","author":"Melville","year":"2022","journal-title":"Structure"},{"issue":"11","key":"10.1016\/j.eclinm.2024.102433_bib18","first-page":"2506","article-title":"Correlation of phenotype with genotype and protein structure in RYR1-related disorders","volume":"265","author":"Todd","year":"2018","journal-title":"J\u00a0Neurol"},{"issue":"5","key":"10.1016\/j.eclinm.2024.102433_bib19","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1213\/ANE.0b013e31828a71ff","article-title":"Ryanodine receptor type 1 gene variants in the malignant hyperthermia-susceptible population of the United States","volume":"116","author":"Brandom","year":"2013","journal-title":"Anesth Analg"},{"issue":"13","key":"10.1016\/j.eclinm.2024.102433_bib20","doi-asserted-by":"crossref","first-page":"e1434","DOI":"10.1212\/WNL.0000000000008872","article-title":"Randomized controlled trial of N-acetylcysteine therapy for RYR1-related myopathies","volume":"94","author":"Todd","year":"2020","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.eclinm.2024.102433_bib21","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1002\/mus.23905","article-title":"The 6-minute walk test and other clinical endpoints in duchenne muscular dystrophy: reliability, concurrent validity, and minimal clinically important differences from a multicenter study","volume":"48","author":"McDonald","year":"2013","journal-title":"Muscle Nerve"},{"issue":"16","key":"10.1016\/j.eclinm.2024.102433_bib22","doi-asserted-by":"crossref","first-page":"e1852","DOI":"10.1212\/WNL.0000000000007319","article-title":"X-linked myotubular myopathy: a prospective international natural history study","volume":"92","author":"Annoussamy","year":"2019","journal-title":"Neurology"},{"issue":"11","key":"10.1016\/j.eclinm.2024.102433_bib23","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/j.jclinepi.2010.04.012","article-title":"Relative to the general US population, chronic diseases are associated with poorer health-related quality of life as measured by the Patient-Reported Outcomes Measurement Information System (PROMIS)","volume":"63","author":"Rothrock","year":"2010","journal-title":"J\u00a0Clin Epidemiol"},{"key":"10.1016\/j.eclinm.2024.102433_bib24","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.redox.2017.03.024","article-title":"Classifying oxidative stress by F(2)-isoprostane levels across human diseases: a meta-analysis","volume":"12","author":"van 't Erve","year":"2017","journal-title":"Redox Biol"},{"issue":"3","key":"10.1016\/j.eclinm.2024.102433_bib25","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/S1474-4422(23)00001-7","article-title":"Antisense oligonucleotide targeting DMPK in patients with myotonic dystrophy type 1: a multicentre, randomised, dose-escalation, placebo-controlled, phase 1\/2a trial","volume":"22","author":"Thornton","year":"2023","journal-title":"Lancet Neurol"},{"issue":"1","key":"10.1016\/j.eclinm.2024.102433_bib26","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.nmd.2018.10.006","article-title":"Functional impairments, fatigue and quality of life in RYR1-related myopathies: a questionnaire study","volume":"29","author":"van Ruitenbeek","year":"2019","journal-title":"Neuromuscul Disord"},{"issue":"42","key":"10.1016\/j.eclinm.2024.102433_bib27","doi-asserted-by":"crossref","first-page":"43838","DOI":"10.1074\/jbc.M403612200","article-title":"Effect of ryanodine receptor mutations on interleukin-6 release and intracellular calcium homeostasis in human myotubes from malignant hyperthermia-susceptible individuals and patients affected by central core disease\u2217","volume":"279","author":"Ducreux","year":"2004","journal-title":"J\u00a0Biol Chem"},{"issue":"1","key":"10.1016\/j.eclinm.2024.102433_bib28","first-page":"83","article-title":"Identification of serum interleukin 6 levels as a disease severity biomarker in facioscapulohumeral muscular dystrophy","volume":"9","author":"Gros","year":"2022","journal-title":"J\u00a0Neuromuscul Dis"},{"issue":"2","key":"10.1016\/j.eclinm.2024.102433_bib29","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1002\/pst.2180","article-title":"Adjusting for bias in the mean for primary and secondary outcomes when trials are in sequence","volume":"21","author":"Rothwell","year":"2022","journal-title":"Pharm Stat"},{"issue":"Pt 8","key":"10.1016\/j.eclinm.2024.102433_bib30","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1093\/brain\/awm096","article-title":"Molecular mechanisms and phenotypic variation in RYR1-related congenital myopathies","volume":"130","author":"Zhou","year":"2007","journal-title":"Brain"}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537024000129?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537024000129?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T23:11:00Z","timestamp":1728601860000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589537024000129"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":30,"alternative-id":["S2589537024000129"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2024.102433","relation":{},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rycal S48168 (ARM210) for RYR1-related myopathies: a phase one, open-label, dose-escalation trial","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2024.102433","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102433"}}